Figure 6. The structures of the Aminophenazone, Pomalidomide and Rosoxacin.

The Aminophenazone was a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013. Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.